Stockopedia
Stockopedia is recognized by thousands of subscribers as the ultimate source for top-notch data, strategies, education, and resources to excel in the markets. Based in Oxford, Stockopedia serves as a research network and community hub that provides investors with tools to analyze, filter, connect, and share investment ideas.
Outlet metrics
Global
#88567
United Kingdom
#6839
Finance/Investing
#66
Articles
-
Dec 11, 2024 |
stockopedia.com | Mark Simpson
In my last article, I screened for turnaround stocks, those that had high Value and Momentum Ranks. Several of the screen results were subject to takeover offers. This may mean that cheap stocks where trading momentum has turned positive are attractive to acquirers. However, we need a much larger sample size than three to say that for definite since it is also possible that the takeover is the source of the positive change in price momentum. It may be an outcome rather than a cause.
-
Jul 26, 2023 |
stockopedia.com | Paul John Scott
Good morning from Paul & Graham!Explanatory notes -A quick reminder that we don’t recommend any stocks. We aim to review trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty.
-
Jul 25, 2023 |
stockopedia.com | Paul John Scott
Good morning from Paul & Graham!Explanatory notes -A quick reminder that we don’t recommend any stocks. We aim to review trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty.
-
Jul 24, 2023 |
stockopedia.com | Paul John Scott
HY update from Diaceutics (LON:DXRX) did not disappoint. This family biz in the med tech sector seems to fly under the radar. Rev + 32%, Order book up 43% since December. Cash £17.9m and no debt even though it is investing for growth as sees company in a sweet spot. FY2022 rev they traded at just over breakeven, so there was no cash burn. 21 of the largest 30 pharma companies are clients. Platform biz transitioning to Saas model.
-
Jul 24, 2023 |
stockopedia.com | Paul John Scott
Morning all, I spent an interesting hour or two reading over yesterdays debate ... as usual, we always find ourselves in interesting times. Complicated times too...so it's unusually hard to forecast, and forecasting is unusually hard! Seems to me the UK may be the blue print... since a fiscally adventurous government had its wings clipped rather quickly...the markets, currency and government bonds said NO. The rest is history....a little less fiscal adventurism please.
Contact details
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →